Cystic Fibrosis Colorectal Cancer Screening Consensus Recommendations

Gastroenterology

Volumn 154, Issue 3, 2018, Pages 736-745.e14

  Hadjiliadis, Denis ^a   Khoruts, Alexander ^b   Zauber, Ann G ^c   Hempstead, Sarah E ^d   Maisonneuve, Patrick ^e   Lowenfels, Albert B ^f   Braid, Amy Leigh ^g   Cullina, Joanne ^g   Daggett, Anne ^g   Fink, Aliza ^g   Gini, Andrea ^g   Harron, Paul F ^g   Lansdorp Vogelaar, Iris ^g   Lieberman, David ^g   Liou, Theodore ^g   Lomas, Paula ^g   Marshall, Bruce ^g   Meyer, Keith ^g   Rustgi, Anil ^g   Shaukat, Aasma ^g   Sabadosa, Kathy ^g   more..

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d CYSTIC FIBROSIS FOUNDATION   (United States)

^e EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^f NEW YORK MEDICAL COLLEGE   (United States)

^g NONE

Author keywords

Cancer; CFTR; Colon; Colonoscopy; Cost Effectiveness Analysis; Cystic Fibrosis; Intestine; Large Bowel; Recommendations; Rectum; Screening

Indexed keywords

LAXATIVE;

ADENOMATOUS POLYP; ARTICLE; CANCER RISK; CANCER SCREENING; COLON CANCER; COLONOSCOPY; COLORECTAL CANCER; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CYSTIC FIBROSIS; DECISION MAKING; ENDOSCOPIST; HEALTH CARE PERSONNEL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE PREPARATION; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; QUALITY OF LIFE; SAFETY; SIGMOIDOSCOPY; ADULT; AGED; CLINICAL DECISION MAKING; COLORECTAL TUMOR; CONSENSUS; CONSENSUS DEVELOPMENT; DECISION SUPPORT SYSTEM; EARLY CANCER DIAGNOSIS; FEMALE; GASTROENTEROLOGY; MALE; MIDDLE AGED; PRACTICE GUIDELINE; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; STANDARDS;

ADULT; AGED; CLINICAL DECISION-MAKING; COLONOSCOPY; COLORECTAL NEOPLASMS; CONSENSUS; CYSTIC FIBROSIS; DECISION SUPPORT TECHNIQUES; EARLY DETECTION OF CANCER; FEMALE; GASTROENTEROLOGY; HUMANS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 85044872308     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2017.12.012     Document Type: Article

References (51)

1. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry 2015 Annual Data Report, 2016, Cystic Fibrosis Foundation, Bethesda, MD.
2. Maisonneuve, P., FitzSimmons, S.C., Neglia, J.P., Campbell, P.W. 3rd, Lowenfels, A.B., Cancer risk in nontransplanted and transplanted cystic fibrosis patients: a 10-year study. J Natl Cancer Inst 95 (2003), 381–387.
3. Maisonneuve, P., Marshall, B.C., Knapp, E.A., Lowenfels, A.B., Cancer risk in cystic fibrosis: a 20-year nationwide study from the United States. J Natl Cancer Inst 105 (2013), 122–129.
4. Fink, A.K., Yanik, E.L., Marshall, B.C., et al. Cancer risk among lung transplant recipients with cystic fibrosis. J Cyst Fibros 16 (2016), 91–97.
5. Neglia, J.P., FitzSimmons, S.C., Maisonneuve, P., et al. The risk of cancer among patients with cystic fibrosis. Cystic Fibrosis and Cancer Study Group. N Engl J Med 332 (1995), 494–499.
6. Alexander, C.L., Urbanski, S.J., Hilsden, R., Rabin, H., MacNaughton, W.K., Beck, P.L., The risk of gastrointestinal malignancies in cystic fibrosis: case report of a patient with a near obstructing villous adenoma found on colon cancer screening and Barrett's esophagus. J Cyst Fibros 7 (2008), 1–6.
7. Brown, J.A., Chaun, H., Mason, A.C., Delayed diagnosis of colon carcinoma in cystic fibrosis. Clin Radiol 55 (2000), 240–242.
8. Gilchrist, F.J., Jones, A.M., Bright-Thomas, R.J., Intussusception and metastatic colon cancer in an adult with cystic fibrosis. J R Soc Med 105:Suppl 2 (2012), S40–S43.
9. Gory, I., Brown, G., Wilson, J., et al. Increased risk of colorectal neoplasia in adult patients with cystic fibrosis: a matched case-control study. Scand J Gastroenterol 49 (2014), 1230–1236.
10. Hernandez-Jimenez, I., Fischman, D., Cheriyath, P., Colon cancer in cystic fibrosis patients: is this a growing problem?. J Cyst Fibros 7 (2008), 343–346.
11. Ibele, A.R., Koplin, S.A., Slaughenhoupt, B.L., et al. Colonic adenocarcinoma in a 13-year-old with cystic fibrosis. J Pediatr Surg 42:10 (2007), E1–E3.
12. Lees, A.N., Reid, D.W., Management dilemma; a woman with cystic fibrosis and severe lung disease presenting with colonic carcinoma: a case report. J Med Case Rep, 2, 2008, 384.
13. McKenna, P.B., Mulcahy, E., Waldron, D., Early onset of colonic adenocarcinoma associated with cystic fibrosis—a case report. Ir Med J 99 (2006), 310–311.
14. Redington, A.N., Spring, R., Batten, J.C., Adenocarcinoma of the ileum presenting as non-traumatic clostridial myonecrosis in cystic fibrosis. Br Med J (Clin Res Ed) 290:6485 (1985), 1871–1872.
15. Samuels, L.E., Amrom, G., Kerstein, M.D., Adenocarcinoma of the ileum in a patient with cystic fibrosis. Dig Dis Sci 40 (1995), 107–108.
16. Siraganian, P.A., Miller, R.W., Swender, P.T., Cystic fibrosis and ileal carcinoma. Lancet, 2(8568), 1987, 1158.
17. Soriano, E., Fischman, D., Cheriyath, P., Membranoproliferative glomerulonephritis in patients with cystic fibrosis: coincidence or comorbidity? A case series. South Med J 101 (2008), 641–645.
18. Billings, J.L., Dunitz, J.M., McAllister, S., et al. Early colon screening of adult patients with cystic fibrosis reveals high incidence of adenomatous colon polyps. J Clin Gastroenterol 48 (2014), e85–e88.
19. Niccum, D.E., Billings, J.L., Dunitz, J.M., et al. Colonoscopic screening shows increased early incidence and progression of adenomas in cystic fibrosis. J Cyst Fibros 15 (2016), 548–553.
20. Than, B.L., Linnekamp, J.F., Starr, T.K., et al. CFTR is a tumor suppressor gene in murine and human intestinal cancer. Oncogene 35:32 (2016), 4179–4187.
21. Starr, T.K., Allaei, R., Silverstein, K.A., et al. A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science 323:5922 (2009), 1747–1750.
22. Gustafsson, J.K., Ermund, A., Ambort, D., et al. Bicarbonate and functional CFTR channel are required for proper mucin secretion and link cystic fibrosis with its mucus phenotype. J Exp Med 209 (2012), 1263–1272.
23. Borowitz, D., CFTR, bicarbonate, and the pathophysiology of cystic fibrosis. Pediatr Pulmonol 50:Suppl 40 (2015), S24–S30.
24. Kreda, S.M., Davis, C.W., Rose, M.C., CFTR, mucins, and mucus obstruction in cystic fibrosis. Cold Spring Harb Perspect Med, 2(9), 2012, a009589.
25. Norkina, O., Burnett, T.G., De Lisle, R.C., Bacterial overgrowth in the cystic fibrosis transmembrane conductance regulator null mouse small intestine. Infect Immun 72:10 (2004), 6040–6049.
26. Munck, A., Cystic fibrosis: evidence for gut inflammation. Int J Biochem Cell Biol 52 (2014), 180–183.
27. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence—SEER 9 Regs Limited Use, Nov 2002 Sub (1973–2000). National Cancer Institute DCCPS Surveillance Research Program Cancer Statistics Branch. http://seer.cancer.gov/faststats/selections.php. Published April 2003, based on November 2002 submission. Accessed January 2017.
28. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry 2014 Annual Data Report, 2015, Cystic Fibrosis Foundation, Bethesda, MD.
29. Knudsen, A.B., Zauber, A.G., Rutter, C.M., et al. Estimation of benefits, burden, and harms of colorectal cancer screening strategies: modeling study for the US Preventive Services Task Force. JAMA 315:23 (2016), 2595–2609.
30. Gini, A., Zauber, A.G., Cenin, D.R., et al. Cost effectiveness of screening individuals with cystic fibrosis for colorectal cancer. Gastroenterology 154 (2018), 556–557.
31. SurveyMonkey Inc. www.surveymonkey.com. Accessed October 2016.
32. Buzzetti, R., Alicandro, G., Minicucci, L., et al. Validation of a predictive survival model in Italian patients with cystic fibrosis. J Cyst Fibros 11 (2012), 24–29.
33. ASGE Standards of Practice Committee, Fisher, D.A., Maple, J.T., et al. Complications of colonoscopy. Gastrointest Endosc 74 (2011), 745–752.
34. Cairns, S.R., Scholefield, J.H., Steele, R.J., et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 59 (2010), 666–689.
35. Syngal, S., Brand, R.E., Church, J.M., et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 110 (2015), 223–262 quiz 263.
36. Meyer, K.C., Francois, M.L., Thomas, H.K., et al. Colon cancer in lung transplant recipients with CF: increased risk and results of screening. J Cyst Fibros 10 (2011), 366–369.
37. Lieberman, D.A., Rex, D.K., Winawer, S.J., et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 143 (2012), 844–857.
38. Yusen, R.D., Edwards, L.B., Kucheryavaya, A.Y., et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-Second Official Adult Lung and Heart-Lung Transplantation Report—2015; Focus Theme: Early Graft Failure. J Heart Lung Transplant 34 (2015), 1264–1277.
39. Atkin, W.S., Valori, R., Kuipers, E.J., et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition—Colonoscopic surveillance following adenoma removal. Endoscopy 44:Suppl 3 (2012), SE151–SE163.
40. Menees, S.B., Kim, H.M., Elliott, E.E., et al. The impact of fair colonoscopy preparation on colonoscopy use and adenoma miss rates in patients undergoing outpatient colonoscopy. Gastrointest Endosc 78 (2013), 510–516.
41. Chokshi, R.V., Hovis, C.E., Hollander, T., et al. Prevalence of missed adenomas in patients with inadequate bowel preparation on screening colonoscopy. Gastrointest Endosc 75 (2012), 1197–1203.
42. Atassi, T., Thuluvath, P.J., Risk of colorectal adenoma in liver transplant recipients compared to immunocompetent control population undergoing routine screening colonoscopy. J Clin Gastroenterol 37 (2003), 72–73.
43. Organ Procurement and Transplantation Network Data. https://optn.transplant.hrsa.gov/data/. Accessed September 30, 2016.
44. Rex, D.K., Optimal bowel preparation—a practical guide for clinicians. Nat Rev Gastroenterol Hepatol 11 (2014), 419–425.
45. Rex, D.K., Bowel preparation for colonoscopy: entering an era of increased expectations for efficacy. Clin Gastroenterol Hepatol 12 (2014), 458–462.
46. Hassan, C., Bretthauer, M., Kaminski, M.F., et al. Bowel preparation for colonoscopy: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy 45 (2013), 142–150.
47. Samarasena, J.B., Muthusamy, V.R., Jamal, M.M., Split-dosed MiraLAX/Gatorade is an effective, safe, and tolerable option for bowel preparation in low-risk patients: a randomized controlled study. Am J Gastroenterol 107 (2012), 1036–1042.
48. Hjelkrem, M., Stengel, J., Liu, M., et al. MiraLAX is not as effective as GoLytely in bowel cleansing before screening colonoscopies. Clin Gastroenterol Hepatol 9 (2011), 326–332 e321.
49. Siddique, S., Lopez, K.T., Hinds, A.M., et al. Miralax with gatorade for bowel preparation: a meta-analysis of randomized controlled trials. Am J Gastroenterol 109 (2014), 1566–1574.
50. Nagler, J., Poppers, D., Turetz, M., Severe hyponatremia and seizure following a polyethylene glycol-based bowel preparation for colonoscopy. J Clin Gastroenterol 40 (2006), 558–559.
51. Lochhead, P., Chan, A.T., Statins and colorectal cancer. Clin Gastroenterol Hepatol 11 (2013), 109–118 quiz e113−e104.